Almirall’s new AI deal with Absci; Jazz partners with Autifony; SAB raises $67M
14 Nov 2023
IPO
Plus, Vittoria raises $15 million, and a spinout from Glasgow and Oxford universities gets £4.3 million in seed funding:
Almirall, Absci partner on AI drug discovery: The companies said Tuesday that they’re working together to develop and commercialize treatments using AI for two dermatological conditions. The Spanish drugmaker will pay Absci up to $650 million, which includes upfront fees and post-approval milestones. Absci’s stock was up about 5% on Tuesday morning, while Almirall’s shares gained about 3%. — Jaimy Lee
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.